# Efficacy of maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed, advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-of-maintenance-olaparib-plus-bevacizumab-according-to-clinical-risk-in/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Philipp Harter,Marie Ange Mouret-Reynier,Sandro Pignata,Claire Cropet,Antonio González-Martı́n,Gerhard Bogner,Keiichi Fujiwara,Ignace Vergote,Nicoletta Colombo,Trine Jakobi Nøttrup,Anne Floquet,Ahmed El‐Balat,Giovanni Scambia,Eva María Guerra Alia,Michel Fabbro,Barbara Schmalfeldt,Anne‐Claire Hardy‐Bessard,Ingo B. Runnebaum,Éric Pujade-Lauraine,Isabelle Ray‐Coquard |
| Citations | 90 |
| DOI | 10.1016/j.ygyno.2021.12.016 |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://doi.org/10.1016/j.ygyno.2021.12.016 |
| OpenAlex ID | https://openalex.org/W4200096254 |
| PMID | 34952708 |
| Type | article |
| Year | 2021 |

## Paper authors

- [Gerhard Bogner](https://scholariq.org/researchers/gerhard-bogner/)

## Paper journal

- [Gynecologic Oncology](https://scholariq.org/journals/gynecologic-oncology/)

## Paper primary topic

- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)

## Paper topics

- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Toxin Mechanisms and Immunotoxins](https://scholariq.org/topics/toxin-mechanisms-and-immunotoxins/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.